--- title: "From Animal to Algorithm: Predicting Drug-Induced Liver Injury" description: This webinar will explore how AI can support more accurate, efficient, and human-relevant approaches to assessing DILI. --- [TransCelerate Logo](https://www.transceleratebiopharmainc.com?hsLang=en) - [Our Work](https://www.transceleratebiopharmainc.com/our-work/) - [About](https://www.transceleratebiopharmainc.com/our-mission/) - [Media & Events](https://www.transceleratebiopharmainc.com/transcelerate-events/) - [Stay Connected](https://www.transceleratebiopharmainc.com/engage-with-us/) Search for: Group 17 Created with Sketch. Hamburger Icon [TransCelerate Logo](https://www.transceleratebiopharmainc.com?hsLang=en) Search for: Group 17 Created with Sketch. - About - [Our Mission](https://www.transceleratebiopharmainc.com/our-mission/) - [Leadership](https://www.transceleratebiopharmainc.com/our-mission/meet-the-people/) - [Our Strategy](https://www.transceleratebiopharmainc.com/our-mission/strategy/) - [Collaborative Model](https://www.transceleratebiopharmainc.com/our-mission/collaborative-model/) - [Members](https://www.transceleratebiopharmainc.com/our-mission/meet-the-members/) - [Our Solutions](https://www.transceleratebiopharmainc.com/our-solutions/) - [Our Solutions](https://www.transceleratebiopharmainc.com/our-solutions/) - [Our Solutions Interactive Tool](https://www.transceleratebiopharmainc.com/our-solutions/) - [All Solutions](https://www.transceleratebiopharmainc.com/all-solutions/) - Advancing Safety Analytics - [Learn more](https://www.transceleratebiopharmainc.com/initiatives/advancing-safety-analytics/) - [Solutions](https://www.transceleratebiopharmainc.com/assets/advancing-safety-analytics-solutions/) - Clinical Content & Reuse - [Learn more](https://www.transceleratebiopharmainc.com/initiatives/clinical-content-reuse/) - [Solutions](https://www.transceleratebiopharmainc.com/assets/clinical-content-reuse-solutions/) - Clinical Data Standards - [Learn more](https://www.transceleratebiopharmainc.com/initiatives/clinical-data-standards/) - Clinical Data Transparency - [Learn more](https://www.transceleratebiopharmainc.com/initiatives/clinical-data-transparency/) - Clinical Research Access & Information Exchange - [Learn more](https://www.transceleratebiopharmainc.com/initiatives/clinical-research-access-information-exchange/) - [Solutions](https://www.transceleratebiopharmainc.com/assets/clinical-research-access-information-exchange-solutions/) - Clinical Research Awareness - [Learn more](https://www.transceleratebiopharmainc.com/initiatives/clinical-research-awareness/) - [Solutions](https://www.transceleratebiopharmainc.com/assets/clinical-research-awareness-solutions/) - Common Serious Adverse Events (SAE) Fields - [Learn more](https://www.transceleratebiopharmainc.com/initiatives/common-serious-adverse-events-sae-fields/) - [Solutions](https://www.transceleratebiopharmainc.com/assets/common-serious-adverse-events-sae-fields/) - Comparator Network - [Learn more](https://www.transceleratebiopharmainc.com/initiatives/comparator-drugs/) - Data Monitoring Committee - [Learn more](https://www.transceleratebiopharmainc.com/initiatives/data-monitoring-committee/) - [Solutions](https://www.transceleratebiopharmainc.com/assets/assets-data-monitoring-committee/) - DataCelerate® - [Learn more](https://www.transceleratebiopharmainc.com/initiatives/datacelerate/) - Digital Data Flow - [Learn more](https://www.transceleratebiopharmainc.com/initiatives/digital-data-flow/) - [Solutions](https://www.transceleratebiopharmainc.com/assets/digital-data-flow-solutions/) - Diversity of Participants in Clinical Trials - [Learn more](https://www.transceleratebiopharmainc.com/initiatives/diversity-of-participants/) - [Solutions](https://www.transceleratebiopharmainc.com/assets/diversity-of-participants-2/) - eConsent - [Learn more](https://www.transceleratebiopharmainc.com/initiatives/econsent/) - [Solutions](https://www.transceleratebiopharmainc.com/assets/econsent-solutions/) - eLabels - [Learn more](https://www.transceleratebiopharmainc.com/initiatives/elabels/) - [Solutions](https://www.transceleratebiopharmainc.com/assets/https-transceleratebiopharmainc-com-assets-elabels/) - eSource - [Learn more](https://www.transceleratebiopharmainc.com/initiatives/esource/) - [Solutions](https://www.transceleratebiopharmainc.com/assets/esource-solutions/) - Historical Trial Data Sharing - [Learn more](https://www.transceleratebiopharmainc.com/initiatives/historical-trial-data-sharing/) - [Solutions](https://www.transceleratebiopharmainc.com/assets/historical-trial-data-sharing-controls-solutions/) - Intelligent Automation Opportunities in Pharmacovigilance - [Learn more](https://www.transceleratebiopharmainc.com/initiatives/intelligent-automation-opportunities-pharmacovigilance-2/) - [Solutions](https://www.transceleratebiopharmainc.com/assets/intelligent-automation-opportunities-pharmacovigilance-solutions/) - Interpretation of Clinical Guidances & Regulations - [Learn more](https://www.transceleratebiopharmainc.com/initiatives/interpretation-of-clinical-guidances-regulations/) - [Solutions](https://www.transceleratebiopharmainc.com/assets/interpretation-of-clinical-guidances-regulations-solutions/) - Interpretation of Pharmacovigilance Guidances & Regulations - [Learn more](https://www.transceleratebiopharmainc.com/initiatives/interpretation-of-pharmacovigilance-guidances-regulations/) - [Solutions](https://www.transceleratebiopharmainc.com/assets/interpretation-of-pharmacovigilance-guidances-regulations-solutions/) - Investigator Registry - [Learn more](https://www.transceleratebiopharmainc.com/initiatives/investigator-registry/) - Modernization of Statistical Analytics - [Learn more](https://www.transceleratebiopharmainc.com/initiatives/modernization-statistical-analytics/) - [Solutions](https://www.transceleratebiopharmainc.com/assets/modernization-of-statistical-analytics-solutions/) - Modernizing Clinical Trial Conduct - [Learn more](https://www.transceleratebiopharmainc.com/initiatives/modernizing-clinical-trial-conduct/) - Patient Experience - [Learn more](https://www.transceleratebiopharmainc.com/initiatives/patient-experience/) - [Solutions](https://www.transceleratebiopharmainc.com/assets/patientexperience/) - Patient Technology - [Learn more](https://www.transceleratebiopharmainc.com/initiatives/patient-technology/) - [Solutions](https://www.transceleratebiopharmainc.com/assets/patient-technology-implementation-framework/patient-technology-assets/) - Pharmacovigilance Agreements Optimization - [Learn more](https://www.transceleratebiopharmainc.com/initiatives/pharmacovigilance-agreements-optimization-pvao/) - Protocol Deviations - [Learn more](https://www.transceleratebiopharmainc.com/initiatives/protocol-deviations/) - [Solutions](https://www.transceleratebiopharmainc.com/assets/protocol-deviations/) - Quality Management System - [Learn more](https://www.transceleratebiopharmainc.com/initiatives/quality-management-system/) - [Solutions](https://www.transceleratebiopharmainc.com/assets/quality-management-system-solutions/) - Real World Data - [Learn more](https://www.transceleratebiopharmainc.com/initiatives/real-world-data/) - Risk Based Monitoring - [Learn more](https://www.transceleratebiopharmainc.com/initiatives/risk-based-monitoring/) - [Solutions](https://www.transceleratebiopharmainc.com/assets/risk-based-monitoring-solutions/) - Shared Investigator Platform - [Learn more](https://www.transceleratebiopharmainc.com/initiatives/shared-investigator-platform/) - [Solutions](https://www.transceleratebiopharmainc.com/assets/shared-investigator-platform/) - Site Qualification and Training - [Learn more](https://www.transceleratebiopharmainc.com/initiatives/site-qualification-and-training/) - [Solutions](https://www.transceleratebiopharmainc.com/assets/site-qualification-and-training/) - Value of Safety Information Data Sources - [Learn more](https://www.transceleratebiopharmainc.com/initiatives/value-of-safety-information-data-sources/) - [Solutions](https://www.transceleratebiopharmainc.com/assets/value-safety-information-data-sources-solutions/) - [Events](https://www.transceleratebiopharmainc.com/transcelerate-events-2/) - [News Center](https://www.transceleratebiopharmainc.com/news-center/) - [Blog](https://www.transceleratebiopharmainc.com/blog/) - [Engage With Us](https://www.transceleratebiopharmainc.com/engage-with-us/) - [COVID-19](https://www.transceleratebiopharmainc.com/covid-19/) - [BioCelerate](https://www.transceleratebiopharmainc.com/biocelerate/home/) - [Member Login](https://www.transceleratebiopharmainc.com/member-login/) - [![twitter_footer_white](https://awarenessandimplementation.transceleratebiopharmainc.com/hubfs/TransCelerateBioPharmainc_May2021/images/twitter_footer_white.png)](https://twitter.com/transcelerate) - [![linkedin_footer_white](https://awarenessandimplementation.transceleratebiopharmainc.com/hubfs/TransCelerateBioPharmainc_May2021/images/linkedin_footer_white.png)](https://www.linkedin.com/company/transcelerate-biopharma-inc-) Translate Select Language Chinese (Simplified) French German Japanese Korean Russian Spanish Powered by [![Google Translate](https://www.gstatic.com/images/branding/googlelogo/1x/googlelogo_color_42x16dp.png)Translate](https://translate.google.com) # TransCelerate BioPharma Webinar Series ## From Animal to Algorithm: Predicting Drug-Induced Liver Injury   ### Date: Thursday, November 12, 2026 ### Time: 9–10:00 a.m. ET   Drug-induced liver injury (DILI) remains a leading cause of drug attrition during clinical development and post-marketing withdrawal, with nearly half of clinically significant DILI events escaping detection in traditional preclinical animal studies. This translational gap has led to the development of AI-enabled new approach methodologies that improve DILI prediction while advancing the 3Rs (replacement, reduction, and refinement) principles. This public webinar will explore how AI can support more accurate, efficient, and human-relevant approaches to assessing DILI.   During this webinar, our speaker will: - Introduce AI-driven approaches for predicting DILI risk and assessing drug-induced toxicities - Share examples from the [FDA's AI4Tox research program](https://www.fda.gov/about-fda/nctr-research-focus-areas/artificial-intelligence), including predictive and generative AI models and AI agents - Explore how these approaches can complement, reduce, or replace selected animal studies - Discuss the [FDA's ISTAND pilot program](https://www.fda.gov/drugs/drug-development-tool-ddt-qualification-programs/innovative-science-and-technology-approaches-new-drugs-istand-program) and its role in advancing novel AI-based drug development tools Collectively, these advances point toward a future in which AI augments regulatory science by improving translational predictivity, accelerating drug development, reducing reliance on animal testing, and enabling safer medicines. Speaker: - [**Weida Tong, Ph.D.,**](https://www.fda.gov/about-fda/science-research-nctr/weida-tong#person-bio) Director of Bioinformatics and Biostatistics, FDA/NCTR *This event does not constitute nor should be considered as any type of endorsement by TransCelerate or its members of any vendor, product, or technology.* *TransCelerate webinars may be recorded in whole or in part.*  [TransCelerate Logo](https://www.transceleratebiopharmainc.com?hsLang=en) - [![twitter_footer_white](https://awarenessandimplementation.transceleratebiopharmainc.com/hubfs/TransCelerateBioPharmainc_May2021/images/twitter_footer_white.png)](https://twitter.com/transcelerate) - [![linkedin_footer_white](https://awarenessandimplementation.transceleratebiopharmainc.com/hubfs/TransCelerateBioPharmainc_May2021/images/linkedin_footer_white.png)](https://www.linkedin.com/company/transcelerate-biopharma-inc-) - [Disclaimer](https://www.transceleratebiopharmainc.com/privacy-policy/) - [Privacy Policy](https://www.transceleratebiopharmainc.com/privacy-policy/) - [Terms of Use](https://www.transceleratebiopharmainc.com/terms/) Group 17 Created with Sketch. Copyright © 2012 - 2026